{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-005043","form_type":"8-K","ticker":"IMMX","cik":"0001873835","company_name":"Immix Biopharma, Inc.","filed_at":"2024-02-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.186043+00:00","generated_at":"2026-06-06T08:32:03.269062+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Immix Biopharma prices $15M public offering of 5.5M shares at $2.71/share","bullets":["Offering of 5,535,055 shares at $2.71 per share; gross proceeds ~$15M before expenses.","Underwriter granted 30-day over-allotment option for up to 783,970 additional shares.","Net proceeds to fund NXC-201 clinical trials, working capital, and general corporate purposes.","Closing expected February 8, 2024; subject to customary conditions.","Directors and officers subject to 90-day lock-up expiring May 8, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-005043","json":"https://secwatch.observer/filing/0001493152-24-005043.json","markdown":"https://secwatch.observer/filing/0001493152-24-005043.md","text":"https://secwatch.observer/filing/0001493152-24-005043.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1873835/000149315224005043/0001493152-24-005043-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1873835/000149315224005043/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T08:32:03.269062+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7da6ad7d548b16c5fa4de7b42ed80387b3a1f385","claim":"Immix Biopharma, Inc. entered into Underwriting Agreement with Titan Partners Group LLC, a division of American Capital Partners, LLC valued at $15 million (effective 2024-02-05).","evidence_excerpt":"On February 5, 2024, Immix Biopharma, Inc. (the “Company”) entered into an Underwriting Agreement (the “Agreement”) with Titan Partners Group LLC, a division of American Capital Partners, LLC (the “Underwriter”), relating to an underwritten offering (the “Offering”) of 5,535,055 shares (“Shares”) of common stock of the Company (“Common Stock”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1873835/000149315224005043/0001493152-24-005043-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"Titan Partners Group LLC, a division of American Capital Partners, LLC"},{"label":"Value","value":"$15 million"},{"label":"Effective","value":"2024-02-05"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}